3.8 C
London
Saturday, November 27, 2021
HomeAll ArticlesBiogen trial of ALS drug fails main goal, but company says data...

Biogen trial of ALS drug fails main goal, but company says data are encouraging

A late-stage trial of Biogen Inc’s (BIIB.O) experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) failed to reach its main goal, but secondary measures and biomarkers showed favorable trends, the company said on Sunday.

Reporting By Deena Beasley; Editing by Andrea Ricci (Reuters)

RELATED ARTICLES
- Advertisment -

Most Popular

Recent Comments

    WP2Social Auto Publish Powered By : XYZScripts.com